Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Oropharyngeal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
14 drugs · 85 active trials
1 drug · 0 active trials
0 drugs · 0 active trials
no drug at this stage
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 5 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nab-paclitaxel | Phase 2 | Phase 2 | 4 | 0 | 0 | 6 | 0 | — | — | Mar 26, 2013 |
| Tislelizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Jun 27, 2023 |
| Aldesleukin | Phase 2 | Phase 2 | 2 | 2 | 0 | 4 | 0 | — | — | Apr 13, 2012 |
| Cemiplimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Nov 30, 2018 |
| Cabozantinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Sep 18, 2018 |
| Ipatasertib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Jul 26, 2022 |
| Prednisone | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Oct 16, 2019 |
| Toripalimab | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | 2026-02 |
| Erlotinib Hydrochloride | Phase 2 | Phase 2 | 1 | 1 | 0 | 14 | 0 | — | — | 2001-12 |
| Fludarabine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 13, 2012 |
| Ipilimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 9, 2013 |
| Tremelimumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Jul 12, 2017 |
| Celecoxib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Nov 27, 2019 |
| Methotrexate | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 9, 2025 |
| Nogapendekin Alfa Inbakicept | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jul 22, 2026 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 2, 2025 |
| Sintilimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 16, 2021 |
| Sorafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 25, 2007 |
| Hydroxyurea | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2001-07 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Jan 19, 2010 |
| Capecitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2009-10 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Alpelisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2016-08 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-05 |
| Irinotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-12 |
| Sunitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-08 |
| Anti-EGFR Monoclonal Antibody | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2016 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-07 |
| Cediranib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-02 |
| Dasatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-07 |
| Infigratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 1, 2018 |
| Nimotuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Porfimer | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2014 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-06 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-11 |
| Valproic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 22, 2012 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.